Summit Therapeutics falls after mixed data from late-stage cancer trial

Shares of drug developer Summit Therapeutics SMMT.O fall 9.7% to $23.66 premarket

Co says its experimental lung cancer therapy ivonescimab in combination with chemotherapy showed a positive trend in overall survival, but "without achieving a statistically significant benefit" in a global late-stage trial

However, co says the therapy showed meaningful improvement in progression free survival or the time patients live without their disease progressing

Co plans to file for marketing approval for ivonescimab, but says the "FDA noted that a statistically significant overall survival benefit is necessary to support marketing authorization," which will weigh into its considerations regarding the timing of filing its US application

SMMT is testing ivonescimab to treat patients with a type of lung cancer who have progressed after prior treatment

There were no new safety signals noted in the late-stage study, co says

Up to last close, stock up 46.9% YTD